集体业绩说明会的公告 重要内容提示： 证券代码：688278 证券简称：特宝生物 公告编号：2023-027 关于参加2023 年半年度制药及生物制品行业 投资者可于 2023 年 9 月 6 日（星期三）16:00 前通过邮件、电话、传真 等形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资 者普遍关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2023 年 8 月 18 日在上海证券交易所披露了公司 2023 年半年度报告，为便于广大投资者更全面 深入地了解公司 2023 年半年度经营成果、财务状况、发展理念，公司参与了由 上海证券交易所主办的 2023 年半年度制药及生物制品行业集体业绩说明会，此 次活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所上 证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司 四、联系人及咨询办法 一、说明会类型 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 20%[2]. - The company's operating revenue for the first half of 2023 reached ¥903,579,420.87, representing a year-on-year increase of 26.40% compared to ¥714,867,789.45 in the same period last year[18]. - Net profit attributable to shareholders for the same period was ¥202,178,809.62, up 51.27% from ¥133,654,117.58 in the previous year[18]. - The net profit after deducting non-recurring gains and losses increased by 54.36%, amounting to ¥232,982,206.21 compared to ¥150,937,683.00 last year[18]. - The basic earnings per share rose to ¥0.50, a 51.52% increase from ¥0.33 in the previous year[19]. - The total revenue for the reporting period is ¥1 billion, with a net profit of ¥647.69 million[48]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 25% year-over-year growth[102]. - The company reported a significant increase in revenue for the first half of 2023, with a year-on-year growth of 25%[109]. Research and Development - The company has allocated RMB 100 million for R&D in innovative drug development for the year 2023, focusing on enhancing drug efficacy and safety[2]. - The company achieved a total R&D investment of approximately ¥167.12 million, representing a 95.90% increase compared to the previous year[43]. - The R&D investment as a percentage of operating revenue was 18.50%, an increase of 6.57 percentage points from 11.93% in the previous year[19]. - Research and development expenses increased by 48.74% to CNY 77.21 million, indicating a strong commitment to new drug development[68]. - The company is actively developing new products, including Pegfilgrastim, which has a longer half-life and lower dosage compared to existing products, providing more treatment options for patients[24]. - The company has launched five products, including Pegbinterferon, which is the world's first 40kD PEGylated interferon α-2b injection, supported by multiple national science and technology projects[22]. - The company has received clinical trial approval for two new drugs and successfully launched one new drug during the reporting period[40]. - The company is expanding its R&D pipeline through collaborations, including a partnership with Aligos Therapeutics, Inc. for hepatitis treatment[57]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market penetration by the end of 2023[2]. - The company has initiated a strategic acquisition of a biotech firm, which is expected to enhance its R&D capabilities and product pipeline[2]. - The company is considering strategic acquisitions to bolster its market position, with a target of identifying two potential candidates by the end of the year[102]. - Market expansion plans include entering three new international markets by Q4 2023[102]. - The company has committed to maintaining a stable shareholding structure, with no major share reductions planned for the next 36 months[103]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥1,863,827,105.25, reflecting a 5.39% increase from ¥1,768,559,647.31 at the end of the previous year[18]. - The company's inventory rose by 18.11% to CNY 153.22 million, reflecting growth in business scale[70]. - The total liabilities decreased to ¥340,696,364.18 from ¥360,959,315.86, a reduction of about 5.6%[151]. - Shareholders' equity increased to RMB 1,523,130,741.07 from RMB 1,407,600,331.45, reflecting a growth of approximately 8.2%[151]. - The total assets of the company at the end of the reporting period are CNY 1,523,130,741.07, reflecting the company's financial position[166]. Compliance and Governance - The board of directors has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[6]. - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board, ensuring effective management and oversight[174]. - The company is committed to maintaining transparency and accountability in its operations and financial disclosures[123]. - The company has not engaged in any violations regarding guarantees during the reporting period[125]. Environmental and Social Responsibility - The company has invested ¥107.30 million in environmental protection during the reporting period[83]. - The company is utilizing distributed photovoltaic power stations on building rooftops to improve energy efficiency and reduce carbon emissions[93]. - The company has engaged in a public welfare project aimed at enhancing liver disease prevention and control in rural areas, screening over 20,000 individuals by July 2023[94]. - The company has implemented a self-monitoring plan for environmental compliance, with regular monitoring results meeting standards[88]. Risks and Challenges - The company has identified potential risks in its operations, including regulatory changes and market competition, and has outlined mitigation strategies in its report[4]. - The company is facing risks related to technological upgrades and potential patent issues that could impact its core competitiveness[59][60]. - The company is committed to addressing the high risks associated with drug development, including potential clinical research failures and regulatory changes[60].

证券代码：688278 证券简称：特宝生物 公告编号：2023-024 监事会在全面审阅公司 2023 年半年度报告及其摘要后，发表意见如下： 1、公司 2023 年半年度报告及其摘要的内容真实、客观地反映了 2023 年半 年度的财务状况和经营成果。 2、公司 2023 年半年度报告及其摘要的编制和审议程序符合中国证券监督 管理委员会、上海证券交易所颁布的有关法律法规、规范性文件以及公司内部 管理制度的各项规定。报告编制过程中，未发现参与报告编制和审议的人员有 违反保密规定的行为。 厦门特宝生物工程股份有限公司 第八届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 厦门特宝生物工程股份有限公司（以下简称"公司"）第八届监事会第九 次会议于 2023 年 8 月 17 日以现场结合通讯表决的方式召开。本次会议已于 2023 年 8 月 4 日以邮件方式通知了全体监事，本次会议由监事会主席刘军先生 主持，会议应到监事 3 人，实到监事 3 人。本次会议的召开符合《公司法》及 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日分别召开第八届董事会第十四次会议及第八届监事会第九次会议，全票审议 通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在不影 响募集资金正常使用的情况下，使用最高额度不超过人民币 5,000 万元（包含 本数）的暂时闲置募集资金适时进行现金管理，授权期限自本次董事会审议通 过之日起 12 个月，在上述额度和期限内，资金可循环滚动使用。公司独立董事 对本次事项发表了明确同意的独立意见，保荐机构国金证券股份有限公司出具 了明确同意的核查意见，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海 证券交易所"自律监管决定书〔2020〕21 号"批准，公司首次公开发行人民币 普通股（A 股）4,650 万股，每股发行价格 8.24 元，本次募集资金总额为人民 币 ...

厦门特宝生物工程股份有限公司 独立董事关于第八届董事会第十四次会议相关事项 的独立意见 我们作为厦门特宝生物工程股份有限公司（以下简称"公司"）的独立 董事，根据《上市公司独立董事规则》《上海证券交易所科创板股票上市规 则》《上市公司治理准则》和《公司章程》等有关规定，在认真审阅公司第 八届董事会第十四次会议相关事项后，发表独立意见如下： 一、《关于公司 2023 年半年度募集资金存放与实际使用情况的专项报告 的议案》 公司 2023 年半年度募集资金的存放与使用符合《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》以及公司募集资金管理制度等相关规定，不存在违规使用募集资金的 情形，不存在变相改变募集资金用途和损害股东利益的情形。公司编制的 《2023 年半年度募集资金存放与实际使用情况的专项报告》真实地反映了报 二、《关于使用部分闲置募集资金进行现金管理的议案》 签字： 签字： 姓名：蒋晓蕙 在确保不影响募投项目建设进展和保证资金安全的前提下，公司使用部 分暂时闲置募集资金进行现金 ...

由于募集资金投资项目建设需要一定周期，结合公司募集资金投资项目的推 进计划，公司部分募集资金存在暂时闲置的情形。 国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程股 份有限公司（以下简称"特宝生物"或"公司"）首次公开发行股票并在科创板 上市的保荐机构，根据《证券发行上市保荐业务管理办法》《科创板上市公司自 律监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则（2020 年 12 月修订）》等有关法律法规和规范性文件的要求，对特宝生物拟将部分闲置 募集资金进行现金管理情况进行了审慎核查，并发表核查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司首 次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海证 券交易所"自律监管决定书〔2020〕21 号"批准，公司首次公开发行人民币普 通股（A 股）4,650 万股，每股发行价格 8.24 元 ...

证券代码：688278 证券简称：特宝生物 公告编号：2023-025 厦门特宝生物工程股份有限公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）根据中国证券监督 管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等有关规定，现将公司 2023 年半年度募集资金存放与实际使用情况专项报 告如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海 证券交易所"自律监管决定书〔2020〕21 号"批准，公司向社会首次公开发行 人民币普通股（A 股）4,650 万股，每股发行价为 8.24 元，本次募集资金总额 为人民币 38,316.00 万元，根据有关规定扣除发行 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 419,307,024.70, representing a year-on-year increase of 21.53%[4] - The net profit attributable to shareholders was RMB 84,173,127.64, reflecting a growth of 46.51% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 102,455,003.37, an increase of 35.62% year-on-year[4] - The basic earnings per share for the period was RMB 0.21, up by 50.00% from the previous year[4] - In Q1 2023, the company reported a net profit of ¥84,173,127.64, an increase of 46.5% compared to ¥57,452,423.77 in Q1 2022[20] - Operating profit for Q1 2023 was ¥118,990,858.09, up 33.5% from ¥89,006,711.83 in the same period last year[20] - Total revenue from sales and services received in Q1 2023 was ¥379,091,244.26, a rise from ¥368,702,244.57 in Q1 2022, reflecting a growth of 2.1%[21] - The company’s total comprehensive income for Q1 2023 was ¥84,173,127.64, an increase of 46.5% from ¥57,452,423.77 in Q1 2022[20] Research and Development - The total R&D investment amounted to RMB 70,109,028.96, which is a significant increase of 71.26% compared to the previous year[4] - The proportion of R&D investment to operating revenue was 16.72%, which increased by 4.85 percentage points year-on-year[5] - The company incurred research and development expenses of ¥37,712,423.75 in Q1 2023, significantly higher than ¥20,347,219.38 in Q1 2022, marking an increase of 85.7%[20] Cash Flow and Assets - The cash flow from operating activities was RMB 21,847,454.23, showing a decrease of 73.66% year-on-year[4] - The company’s cash flow from operating activities in Q1 2023 was ¥21,847,454.23, down 73.7% from ¥82,949,425.82 in Q1 2022[22] - The company's cash and cash equivalents increased to CNY 520,779,757.78 from CNY 301,240,536.26 at the end of 2022, representing a growth of 73%[14] - The company’s cash and cash equivalents at the end of Q1 2023 totaled ¥519,870,257.78, an increase from ¥491,191,572.08 at the end of Q1 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,845,004,186.33, an increase of 4.32% from the end of the previous year[5] - As of March 31, 2023, total current assets were CNY 961,471,381.59, slightly up from CNY 955,610,910.65 at the end of 2022[14] - Non-current assets totaled CNY 883,532,804.74 as of March 31, 2023, compared to CNY 812,948,736.66 at the end of 2022, indicating an increase of 8.7%[15] - The company's total liabilities decreased to CNY 353,230,727.24 from CNY 360,959,315.86 at the end of 2022, a reduction of 2%[16] - The retained earnings increased to CNY 614,970,718.03 from CNY 530,797,590.39, reflecting a growth of 15.8%[17] Shareholder Information - The company reported a total of 5,888 common shareholders at the end of the reporting period[8]

证券代码：688278 证券简称：特宝生物 公告编号：2023-014 厦门特宝生物工程股份有限公司关于 参加 2022 年度生物制品专场集体业绩说明会的公告 投资者可于 4 月 25 日（星期二）16:00 前通过邮件、电话、传真等形式 将需要了解和关注的问题提前提供给公司，公司将在文字互动环节对投资者普遍 关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日在上海证券交易所披露了公司 2022 年年度报告，为便于广大投资者更全面深 入地了解公司 2022 年度经营成果、财务状况和发展理念，公司参与了由上海证 券交易所主办的 2022 年度生物制品专场集体业绩说明会，此次活动将采用视频 和网络文字互动的方式举行，投资者可登录上海证券交易所上证路演中心 （http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以视频和网络互动形式召开，公司将针对 2022 年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、方式 ...